tac 278 has been researched along with Lung Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arimori, S; Furue, H; Ikenaga, M; Iketa, T; Komita, T; Nagao, T; Ohki, S; Satoh, H; Watanabe, K; Yamamoto, S | 1 |
2 other study(ies) available for tac 278 and Lung Neoplasms
| Article | Year |
|---|---|
[Phase II study of a new fluorinated pyrimidine, ethyl (+/-)-t-6-butoxy-5-fluoro-2, 4-dioxohexahydropyrimidine-r-5-carboxylate (TAC-278)].
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms | 1982 |
[TAC-278. A new 5-FU derivative, by the oral route for its efficacy and safety in 36 patients with advanced cancers].
Topics: Adult; Aged; Blood Platelets; Drug Evaluation; Female; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Large; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Stomach Neoplasms | 1982 |